PipelineReview.com4h
Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL
BOSTON, MA, USA I March 5, 2025 I Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stage biotech company dedicated to developing innovative universal CAR-T ...
PipelineReview.com4h
TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
CAMBRIDGE, UK I March 05, 2025 I TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative ...
PipelineReview.com4h
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
DUBLIN, Ireland and DURHAM, NC, USA I March 5, 2025 I Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) and Chimerix (Nasdaq: CMRX) (“Chimerix”), today announced the companies have ...
PipelineReview.com1d
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
NEW YORK, NY, USA I March 03, 2025 I IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell ...
PipelineReview.com1d
FDA Approves Genentech’s TNKase®in Acute Ischemic Stroke in Adults
TNKase ® (tenecteplase) is the first stroke medicine approved by the FDA in nearly 30 years – – Single five-second intravenous bolus provides faster and simpler administr ...
PipelineReview.com1d
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
SUZHOU, China I March 3, 2025 I CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and ...
PipelineReview.com1d
Bayer starts Phase II clinical study with BAY 2927088 in metastatic or unresectable HER2 mutant solid tumors
First patient enrolled in the Phase II panSOHO basket trial; this is the third BAY 2927088 clinical trial in patients with HER2- activating mutations ...
PipelineReview.com1d
Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA
LOS ANGELES, CA, USA I March 03, 2025 I Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an ...
PipelineReview.com1d
Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
REDWOOD CITY, CA, USA I March 03, 2025 I Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy to preserve ...
PipelineReview.com1d
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and mAbxience (“mAbxience”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its ...
PipelineReview.com2d
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo ...
PipelineReview.com2d
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity
NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical ...